7th April 2020
To analyse the effects of a hydroxychloroquine
ExactCure, a start-up supported by EIT Health that uses technology to improve the levels of medicine doctors prescribe, created a personalised digital patient model to analyse the effects of a hydroxychloroquine-based treatment for COVID-19. This digital clone can help doctors find the most adequate treatment for each patient by implementing each individual’s physical parameters into the model.
Following recent speculation about the capacity of hydroxychloroquine as a treatment for patients with COVID-19, the city of Marseille’s public hospital (AP-HM) solicited ExactCure to create a personalised health model around this molecule.
In 48 hours, ExactCure created a virtual model that allows personalised medication by allowing for refined dosages that into account various parameters such as a patients age and weight, and hours of intake, in order to stabilise blood concentration as much as possible.
The larger scale development of this solution would reduce the risks associated with treatment errors, and would allow for more rapid tests of this treatment.
ExactCure has participated in several EIT Health programmes aimed at acceleration, including the EIT Health Headstart programme in 2018, the Living Lab and Test Beds programme in 2019 and the Network Call in 2019.
Find out more here: https://www.exactcure.com/
Philips ultrasound OK'd for COVID-19 lung, cardiac care
FDA approves use of firm's ultrasound portfolio to manage COVID-19-related complications
Backed by EIT Health Alumni, DAP aids care facilities
Digital Aid Project seeks to aid nursing homes, rehabilitation centres and mental health facilities
AstraZeneca to cooperate on Oxford's vaccine effort
Firm ready to facilitate distribution of Oxford University team's vaccination, which is already undergoing trials